The emergence of HIV resistance and new antiretrovirals: Are we winning?

Drug Resistance Updates

Volumn 7, Issue 3, 2004, Pages 163-167

  Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

BMS 488043; Drug resistant HIV; GW678248; GW873140; HIV protease; Mother to child transmission; NNRTIs; NRTIs; Reverse transcriptase; Reverset; SCH D; SPD754; TMC114

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMD 070; AMD 887; ANTIRETROVIRUS AGENT; APLAVIROC; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ELVUCITABINE; GW 678248; KRH 2731; LAMIVUDINE; MARAVIROC; NEVIRAPINE; PRO 140; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPD 754; TENOFOVIR; TIBOTEC; UNCLASSIFIED DRUG; ZIDOVUDINE;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG TOLERANCE; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV; MUTATION;

EID: 3543080449     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2004.06.001     Document Type: Conference Paper

References (34)

1. Ait-Khaled M., Griffin P., et al. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy. Antivir. Ther. 7:2002;43-51
2. Bethell, R., Adams, J., De Muys, J., et al., 2004. Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 138.
3. Bonneau, P.R., Doyon, L., Duan, J., et al., 2004. Characterization of a novel series of nevirapine-like next-generation NNRTI with broad antiviral potency against NNRTI-resistant HIV. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 530.
4. Cahn, P., Lange, J., Cassetti, I., et al., 2003. Anti HIV-1 activity of SPD754, a new NRTI: results of a 10-day monotherapy study in treatment-naive HIV patients. In: Proceedings of the Second International AIDS Society Conference on HIV Pathogenesis and Treatment. Abstract LB15.
5. Charpentier, C., Morand-Joubert, L., Chene, G., Girard, P.-M., Clavel, F., Hance, A.J., 2004. Detection of pre-existing minority viral populations contributing to the evolution of resistance to protease inhibitors. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 57.
6. Collins, P., Shiveley, L., Anderson, C., Bethell, R., 2004. Analysis of the genotypes of viruses isolated from patients after 10 days monotherapy with SPD754. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 526.
7. Demarest, J., Adkison, K., Sparks, S., et al., 2004. Single and multiple dose escalation study to investigate the safety, pharmacokinetics, and receptor binding of GW873140, a novel CCR5 receptor antagonist in healthy subjects. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 139.
8. De Meyer, S., Van Marck, H., Van Den Bulcke, T., et al., 2004. Phenotypic and genotypic profiling of TMC114, a potent next-generation P.I., against some 1600 recent PI-resistant clinical isolates. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 620.
9. Elion, R., Cohen, C., DeJesus, E., et al., 2004. COL40263: resistance and efficacy of once-daily Trizivir and tenofovir DF in antiretroviral naive subjects. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 53.
10. Franti, M., Ramos, L., Maloveste, S., et al., 2004. Control of HIV-1 replication in the hu-PBL-SCID mouse model by an anti-CCR5 monoclonal antibody. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 537.
11. Hanna, G., Lalezari, J., Hellinger, J., et al., 2004. Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1-infected subjects. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 141.
12. Hanna, G., Yan, J.-H., Fiske, W., et al., 2004. Safety, tolerability, and pharmacokinetics of a novel, small-molecule HIV-1 attachment inhibitor, BMS-488043, after single and multiple oral doses in healthy subjects. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 535.
13. Jemsek, J., Hutcherson, P., Harper, E., 2004. Poor virologic and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir D.F. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 51.
14. Johnson, B., Tarby, C., Srivastava, A., et al., 2004. Novel tricyclic non-nucleoside reverse transcriptase inhibitors with improved resistance profiles. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 531.
15. Jourdain, G., Ngo-Giang-Huong, N., Tungyai, P., et al., 2004. Exposure to intrapartum single-dose nevirapine and subsequent maternal 6-month response to NNRTI-based regimens. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 41LB.
16. Kozal, M., Amico, R., Chiarella, J., et al., 2004. Continuing high-risk sexual behavior and increasing antiretroviral resistance among HIV patients in care helps explain the rising prevalence of resistance among new HIV infections. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 35LB.
17. Lallemant, M., Jourdain, G., Le Coeur, S., et al., 2004. A randomized, double-blind trial assessing the efficacy of single-dose perinatal nevirapine added to a standard zidovudine regimen for the prevention of mother-to-child transmission of HIV-1 in Thailand. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 40LB.
18. Landman, R., Peytavin, G., Descamps, D., et al., 2004. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the tonus study. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 52.
19. Lin, P.F., Ho, H.T., Gong, Y.F., et al., 2004. Characterization of a small molecule HIV-1 attachment inhibitor BMS-488043: virology, resistance and mechanism of action. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 534.
20. Little, S.J., Koelsch, K.K., Ignacio, C.C., et al., 2004. Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 36LB.
21. Locas, C., Ching, S., Damment, S., 2004. Safety profile of SPD754 in cynomolgus monkeys treated for 52 weeks. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 527.
22. Maeda, K., Ogata, H., Harada, S., et al., 2004. Determination of binding sites of a unique CCR5 inhibitor AK602 on human CCR5. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 540.
23. Martinson, N., Morris, L., Gray, G., et al., 2004. HIV resistance and transmission following single-dose nevirapine in a PMTCT cohort. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 38.
24. Mellors, J., Palmer, S., Nissley, D., et al. Low-frequency NNRTI-resistant variants contribute to failure of efavirenz-containing regimens. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 39.
25. Murakami, T., Yoshida, A., Tanaka, R., et al., 2004. KRH-2731: an orally bioavailable CXCR4 antagonist is a potent inhibitor of HIV-1 infection. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 541.
26. Murphy, R.L., Schurmann, D., Beard, A., Cartee, L., Schinazi, R.F., Otto, M.J., 2004. Tolerance and potent anti-HIV-1 activity of Reverset following 10 days of mono-therapy in treatment-naïve individuals. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 137.
27. Murphy, R.L., Schürmann, D., Kravec, I., et al., 2003. Pharmacokinetics, safety and antiviral activity of the nucleoside Reverset following single doses in HIV-1 infected patients. In: Proceedings of the Second International AIDS Society Conference on HIV Pathogenesis and Treatment. Abstract 545.
28. Newell M.L., Gibb D.M. A risk-benefit assessment of zidovudine in the prevention of perinatal HIV transmission. Drug Saf. 12:1995;274-282
29. Roberts, G., Porter, D., Boone, L., et al., 2004. Kinetic and thermodynamic parameters for binding of the non-nucleoside inhibitors GW678248 and GW695634 to wild type and 12 mutants of HIV-1 reverse transcriptase. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 529.
30. Schinazi R.F., Mellors J., Bazmi H., et al. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Antimicrob. Agents Chemother. 46:2002;1394-1401
31. Schols, D., Vermeire, K., Hatse, S., et al., 2004. In vitro anti-HIV activity profile of AMD887, a novel CCR5 antagonist, in combination with the CXCR4 inhibitor AMD070. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 539.
32. Schurmann, D., Rouzier, R., Nougarede, R., et al., 2004. SCH D: antiviral activity of a CCR5 receptor antagonist. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 140LB.
33. Van Herrewege, Y., Michiels, J., Kara, Z., et al., 2004. Diarylpyrimidines and diaryltriazines constitute a new class of highly active non-nucleoside reverse transcriptase inhibitors. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 528.
34. Westby, M., Whitcomb, J., Huang, W., et al., 2004. Reversible predominance of CXCR4 utilising variants in a non-responsive dual tropic patient receiving the CCR5 antagonist UK-427,857. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Abstract 538.